Ajinomoto expands its manufacturing arrangement with AstraZeneca

April 5, 2021

Agreement will now include fill-finish services at San Diego facility

Ajinomoto Bio-Pharma Services, a contract development and manufacturing organization (CDMO), and AstraZeneca are expanding their manufacturing agreement to include drug product manufacturing.

This agreement expands the extent of Aji Bio-Pharma's service offerings to AstraZeneca to also feature aseptic fill-finish services at its San Diego, CA, facility, along with small molecule manufacturing services proceeding in Belgium.

"We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, Ajinomoto’s global account manager. "Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients."

Aji Bio-Pharma has sites in India and Japan as well.